作者: Yongquan Tang , Zhihong Liu , Zijun Zou , Jiayu Liang , Yiping Lu
DOI: 10.1155/2018/9362108
关键词:
摘要: Background. The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy. We aimed to assess the prognostic benefits after resection ACC patients without distant metastasis. Methods. PubMed, WoS, Embase, and Cochrane Library databases were systematically searched. Recurrence-free survival (RFS) overall (OS) adopted as measurements. A meta-analysis was conducted based hazard ratio (HR) with 95% confidence interval (CI). study included only if enrolled underwent chemotherapy except mitotane. Results. total 5 retrospective studies reporting 1249 for this meta-analysis. showed that significantly associated prolonged RFS (HR = 0.62; 95%CI, 0.42-0.94; P < 0.05) OS 0.69; 0.55-0.88, 0.05). Conclusion. After comprehensive review, current evidence suggests decreases recurrence rate mortality metastasis, but these findings need further demonstration from prospective controlled trials.